|Slideshows|December 1, 2019

Climate Psychiatry Year in Review

Author(s)Natalie Timoshin, Laurie Martin

Climate medicine: What was once on the radar of just a handful of physicians has exploded into awareness, alarm, and sometimes debate and skepticism. No matter how you look at it, psychiatrists are on the front lines.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe Now!

Related Content

BPL-003: Positive Phase 2b Open-Label Extension Study Data

ByLeah Kuntz

November 10th 2025

Caplyta FDA Approval: Benefits for Patients, With Roger McIntyre, MD

ByRoger S. McIntyre, MD, FRCPC

November 6th 2025

FDA Approves Caplyta for Adjunctive Treatment of Major Depressive Disorder

ByLeah Kuntz

November 6th 2025

Helping Patients Navigate the Halloween Season and Sensory Overload: In Conversation With Richard W. Miller, MD

ByLeah Kuntz,Richard W. Miller, MD

October 31st 2025

Novel PDA10A Inhibitor for Schizophrenia in Development, Discussion With Maciej Wieczorek, MD

Novel PDA10A Inhibitor for Schizophrenia in Development, Discussion With Maciej Wieczorek, PhD

ByMaciej Wieczorek, PhD

October 27th 2025

Latest CME

Video

PER Psych Summit: Integrating Shared Decision-Making Into Management Plans for Patients With Schizophrenia

Sanjai Rao, MD, DFAPA; Dawn I. Velligan, PhD

In-Person Event

Southern Florida Psychiatry Conference

November 21-22, 2025

Register now!

Case-based Simulation

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Nicholas Doher, DO; Babak Tousi, MD

In-Person + Virtual Event

Real Psychiatry 2026

January 23-24, 2026

Video

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Video

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Video

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Climate Psychiatry Year in Review

Newsletter

Related Content

BPL-003: Positive Phase 2b Open-Label Extension Study Data

Caplyta FDA Approval: Benefits for Patients, With Roger McIntyre, MD

FDA Approves Caplyta for Adjunctive Treatment of Major Depressive Disorder

Helping Patients Navigate the Halloween Season and Sensory Overload: In Conversation With Richard W. Miller, MD

Novel PDA10A Inhibitor for Schizophrenia in Development, Discussion With Maciej Wieczorek, PhD

Latest CME

PER Psych Summit: Integrating Shared Decision-Making Into Management Plans for Patients With Schizophrenia

Southern Florida Psychiatry Conference

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Real Psychiatry 2026

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Optimizing Care for Patients With Tardive Dyskinesia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

Patients Dosed With Psilocybin in Phase 2b Trial for Adjustment Disorder in Palliative Care

BPL-003: Positive Phase 2b Open-Label Extension Study Data

Identifying and Treating High Functioning Substance Use Disorder

Let’s Get Competitive

Conversations on Trauma, Music, and Healing, With Frank Clark, MD and Brooke Richey